About Christoph Schäfer

This author has not yet filled in any details.
So far Christoph Schäfer has created 54 blog entries.

CIS Pharma initiates a proof of concept program for its novel polymer-drug carriers tailored to radioisotopes

Bubendorf, Switzerland, Wednesday, September 5, 2019 - CIS Pharma has signed a research agreement with the Paul Scherer Institute, Switzerland. The program comprises an invitro and invivo program for the [...]

CIS Pharma summer event at the Rhine Falls

Schaffhausen, Switzerland, Friday, July 19,  2019 - During our Summer Event we take a boat ride along the banks of the Rhine Falls in Schaffhausen. The spectacular falls offers a [...]

FDA approves novel antibody-drug conjugate Polivy

Maryland, USA, Monday, June 10, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Polivy - polatuzumab vedotin-piiq, Roche - in combination with the chemotherapy bendamustine and [...]

CIS Pharma initiates a new R&D program in the field of PEEK implants

Bubendorf, Switzerland, Thursday, April 25, 2019 - In a new research program the surface of PEEK medical implants will modified to enhance osteointegration and soft-tissue compatibility. The modification is targeting the [...]

CIS Pharma Christmas event in Bern

Bern, Switzerland, Friday, December 7, 2018 - For the end of year event, the team of CIS Pharma sets out to Bern, the capital of Switzerland. Our city guide Domenico [...]

CIS Pharma starts collaboration with the Paul Scherer Institute on antibody-radionuclide conjugates

Bubendorf, Switzerland, Thursday, November 22, 2018 - CIS Pharma has identified the group of Prof. Schibli and Dr. Behe from the Paul Scherer Institute, ETH,  as potential partners for its [...]

Nordic Nanovectors presents promising Phase 1 study results on its antibody-radionuclide conjugate Betalutin

Philadelphia, USA, Thursday, November 1, 2018 - Betalutin is an antibody-radionuclide conjugate, ARC, representing a combination of lilotomab for targeting CD37, a protein that specifically exists on the surface of [...]

Novartis successfully completes acquisition of Endocyte and its new antibody-radionuclide conjugate

Zurich, Switzerland, Thursday, October 18, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies [...]

CIS Pharma team attends CPhI Worlwide 2018 in Madrid

Madrid, Spain, Tuesday to Thursday, October 9 to 11, 2018 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Madrid. The [...]

CIS Pharma summer event in Basel

Basel, Switzerland, Tuesday, September 11, 2018 - During our Summer Event we dive into the multifaceted side of Basel, Kleinbasel, at the northern banks of the river Rhine. Our trip [...]